Wockhardt has reported results for third quarter ended December 31, 2014.
The company has reported a net loss of Rs 25.41 crore for the quarter under review as compared to a net profit of Rs 25.82 crore for the same quarter in the previous year. Total income of the company has decreased 7.41% at Rs 450.21 crore for Q3FY15 as compared Rs 486.22 crore for the corresponding quarter previous year.
On the consolidated basis the company’s net profit after taxes, minority interest and share of profit / (loss) of associates rose 14.06% to Rs 347.25 crore for the Q3 FY15 as compared to Rs 304.45 crore in Q3 FY14. Moreover, the total income increased 4.03% to Rs 1376.03 crore in the quarter under review as compared to Rs 1322.72 crore in the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: